Iveric Bio given exclusive permission to develop, commercialize new formulations of Zimura
Through an exclusive license agreement, Iveric Bio will develop and commercialize new formulations of Zimura using silica-based sustained release technology by DelSiTech, according to a press release from Iveric Bio.
The agreement coincides with Iveric Bio’s lifecycle expansion plan for Zimura (avacincaptad pegol), as the company is looks to develop sustained release technologies for the treatment of age-related macular degeneration. According to the release, these technologies may be able to address patients being treated for geographic atrophy (GA) and intermediate AMD.
Iveric Bio plans to initiate a clinical trial later this year on the current formulation of the drug in patients with intermediate AMD to explore its potential for treating earlier stages of AMD, according to the release.
“We are thrilled to collaborate with the DelSiTech team on investigating additional sustained release formulations for Zimura with their drug delivery expertise and advanced technology and look forward to evaluating a sustained release formulation in GA and potentially earlier stages of AMD,” Pravin U. Dugel, MD, president of Iveric Bio, said in the release. “Previously reported post-hoc analyses from GATHER1 suggest that Zimura may have the potential to impact AMD in early stages before atrophy occurs in patients. We believe Zimura, which is a chemically synthesized RNA aptamer, is amenable to injectable sustained-release formulations.”
Iveric Bio will pay DelSiTech an upfront payment of 1,250,000, as well as development and commercial milestones and royalties on net sales of licensed products, according to the release.
Read more about